Loading clinical trials...
Loading clinical trials...
To evaluate the effectiveness of RXI-109 in reducing the recurrence of keloid formation following elective keloid excision.
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
RXi Pharmaceuticals, Corp.
NCT07336368 · Keloid Scars, Hypertrophic Scars
NCT06373458 · Keloid
NCT06806735 · Keloid Scar Following Surgery, Scars, Hypertrophic, and more
NCT07014280 · Keloids
NCT06965088 · Patients With Keloid Scar
Miami, Florida
St Louis, Missouri
San Cristóbal
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions